CAR-T– tag –
-
ASCO 2026 Highlights CAR-T Cell Therapy Evolution in Multiple Myeloma: Focus on Rapid Manufacturing, Dual-Targeting, and Lentiviral Approaches
YouTube (OncUpdates) USA Overview A YouTube video featuring Dr. Hamza Hashmi discussed the latest advancements in CAR-T therapy for multiple myeloma at ASCO 2026. CAR-T therapy has evolved from a last-resort treatment to a viable option ... -
CDMO Signal Ranks Lentiviral Vector (LVV) CDMOs: GMP Standards and Robust Assays Key for Selection
CDMO Signal USA Overview CDMO Signal published its ranking of Lentiviral Vector (LVV) CDMOs based on Signal Score. LVVs are critical in ex vivo gene therapies for engineering CAR-T cells and modifying hematopoietic stem cells, necessitat... -
Qihan Biotech Receives FDA RMAT and Breakthrough Therapy Designations for Universal Dual-Target CAR-T Therapy, Supported by PackGene Biotech’s CDMO Expertise
PackGene Biotech China Overview Qihan Biotech announced that its universal dual-target CAR-T therapy received both Regenerative Medicine Advanced Therapy (RMAT) and Breakthrough Therapy designations from the U.S. FDA. PackGene Biotech, a... -
Miltenyi Biotec’s Global T-Cell Manufacturing Platform Integrates Automated Closed Systems, Cuts Manual Labor by Over 70%, Achieves High Yields
Bioprocess Online Germany Overview Miltenyi Biotec proposes that global scaling of TCR-T cell manufacturing requires a fundamental process redesign, integrating six key production steps into a single automated, closed system. This integr... -
CCRM, OmniaBio, and Avectas Partner to Enhance Cell Therapy Manufacturing with Automated Platform Evaluation
BioSpace Canada Overview CCRM and its CDMO subsidiary, OmniaBio Inc., have partnered with Avectas Limited to evaluate an automated, integrated, and scalable cell therapy manufacturing platform. This collaboration aims to explore how Avec... -
New Market Pitch Evaluates Top Cell Therapy Startups Including Orca Bio, Cellares, and Kelonia: Differentiated by Clinical, Manufacturing, and Strategic Advancements
New Market Pitch USA Overview New Market Pitch selected ten leading cell therapy startups—Orca Bio, Kyverna, Cabaletta Bio, Cellares, Immatics, Iovance, Sana, Kelonia, Orna, and Dispatch Bio—evaluating their regulatory maturity, clinical... -
Nkarta Accelerates Clinical Development of Off-the-Shelf NK Cell Therapies NKX019 and NKX101 from Healthy Donors
Umbrex USA Overview Nkarta, a clinical-stage biotechnology company, focuses on off-the-shelf natural killer (NK) cell therapies, utilizing a platform that genetically engineers and cryopreserves healthy donor-derived NK cells. Its lead p... -
ASCO 2026 Emphasizes ‘Less Is More’: In Vivo CAR-T and Minimally Invasive, Highly Efficient Cancer Therapies Take Center Stage
Everest Clinical Research USA Overview ASCO 2026 highlighted 'Less Is More' as a guiding principle for future cancer care, with significant attention on evolving CAR-T cell therapies, particularly in vivo CAR-T approaches that engineer i... -
Cell and Gene Therapy’s Next Frontier: Overcoming Manufacturing, Commercial, and Clinical Infrastructure Challenges Beyond Scientific Discovery
Drug Discovery News USA Overview The primary challenge for cell and gene therapies is shifting from scientific discovery to building robust manufacturing, commercial, and clinical infrastructure. Issues like insufficient durability due t... -
Qihan Biotech’s Universal Dual-Target Hypoimmune CAR-T Therapy QT-019B Receives FDA RMAT and Breakthrough Therapy Designations
PackGene Biotech China Overview Qihan Biotech's universal dual-target CAR-T therapy, QT-019B, has received both FDA Regenerative Medicine Advanced Therapy (RMAT) and Breakthrough Therapy Designations (BTD). This off-the-shelf allogeneic ...
